Please ensure Javascript is enabled for purposes of website accessibility

Rite Aid Shares Slide 8% After Report of Increased FTC Activity

By Daniel Miller – May 16, 2017 at 5:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmacy chain's 2017 stock price decline continued on word that the Federal Trade Commission is seeking more information relating to its planned sale to Walgreens.

What happened?

Shares of Rite Aid Corporation (RAD 9.76%), one of the nation's leading drug store chains, with a strong presence on both coasts, are down 8% on Tuesday after the Federal Trade Commission reportedly issued civil investigative demands for information about Walgreens' (WBA 1.37%) plans to acquire the company.

So what

Civil investigative demands are essentially requests for more information pursuant to a potential lawsuit challenging a merger or acquisition. That doesn't mean it's a sure thing the FTC will attempt to block this deal, but it's certainly not an encouraging development.

"We are pleased to have certified completion of our submission of documents and information to the FTC in connection with the Second Request," said Stefano Pessina, executive vice chairman and CEO of Walgreens Boots Alliance, in a press release. "We will continue to work closely with the FTC regarding the pending transaction."

Consumer shopping at a pharmacy store.

Image source: Getty Images.

Now what

In my opinion, this deal going through in some form still remains more likely than not, but the details certainly continue to grow cloudier. Between Rite Aid and Walgreens, the former definitely has more to lose in this situation, and the graph below shows investors' increasing pessimism about its outlook as this saga has trudged on.

RAD Chart

RAD data by YCharts

If the acquisition takes place, Walgreens will become the largest retail pharmacy chain in the U.S., substantially increasing its market penetration and purchasing power. However, if the deal founders, there will be other ways Walgreens could use the cash it was dedicating to it to return value to shareholders, so investors on that side shouldn't lose sleep.

Daniel Miller has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.